David Harrich

5.4k citations

87 papers · 4.5k indexed · 2 hit papers · h-index 34

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment

Papers in

Virology 58
- HIV Research and Treatment 58
Infectious Diseases 43
- HIV/AIDS drug development and treatment 31
- Viral Infections and Vectors 6

Co-authors: Richard B. Gaynor F Wu Haran Sivakumaran Ronald T. Mitsuyasu Joseph A. Garcia León F. Garcı́a-Martı́nez S.-H.I. Ou David A. Jans
Journals: Journal of Virology (19 papers)The EMBO Journal (7 papers)Virology Journal (6 papers)PLoS ONE (4 papers)Retrovirology (3 papers)
Partner nations: Australia United States China

In The Last Decade

David Harrich

87 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus 2012 · 523 citations

Peers

Countries citing papers authored by David Harrich

Since Specialization

Citations

This map shows the geographic impact of David Harrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Harrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Harrich more than expected).

Fields of papers citing papers by David Harrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Harrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Harrich. The network helps show where David Harrich may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Harrich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Harrich Line = papers co-authored together David Harrich links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Novel Delivery Systems for Oral Administration of Enfuvirtide: New Treatment Options for HIV/AIDS Advanced Therapeutics ·Chetakar Jha, Zhi Qu, Vinod Kumar, V. A. Poselov, Youzhi Wu, Min‐Hsuan Lin, David Harrich, Felicity Y. Han	2024	2
2	Low back pain and osteoarthritis pain: a perspective of estrogen Bone Research ·Chetakar Jha, Shihui Chen, David M. Klyne, David Harrich, Wenyuan Ding, Sidong Yang, Felicity Y. Han	2023	58
3	An Appetite for Destruction: Detecting Prey-Selective Binding of α-Neurotoxins in the Venom of Afro-Asian Elapids Toxins ·Richard J. Harris, Christina N. Zdenek, David Harrich, Nathaniel Frank, Bryan G. Fry	2020	41
4	Evolutionary Interpretations of Nicotinic Acetylcholine Receptor Targeting Venom Effects by a Clade of Asian Viperidae Snakes Neurotoxicity Research ·Richard J. Harris, Christina N. Zdenek, Jordan Debono, David Harrich, Bryan G. Fry	2020	23
5	Assessing the Binding of Venoms from Aquatic Elapids to the Nicotinic Acetylcholine Receptor Orthosteric Site of Different Prey Models International Journal of Molecular Sciences ·Richard J. Harris, Nicholas J. Youngman, Christina N. Zdenek, Marek Střelecký, Amanda Nouwens, Wayne C. Hodgson, David Harrich, Nathan Dunstan, José A. Portes-Junior, Bryan G. Fry	2020	18
6	A Taxon-Specific and High-Throughput Method for Measuring Ligand Binding to Nicotinic Acetylcholine Receptors Toxins ·Christina N. Zdenek, Richard J. Harris, Sanjaya Kuruppu, Nicholas J. Youngman, James Dobson, Jordan Debono, SONGÜL ŞAHİN, Ian C. P. Smith, Ann-Cathrine Kroon, David Harrich, W. Wang, Nathan Dunstan, Luke Allen, Bryan G. Fry	2019	34
7	eEF1A demonstrates paralog specific effects on HIV-1 reverse transcription efficiency Virology ·Dongsheng Li, Daniel J. Rawle, 由佳理寺林, 煕史原田, Min‐Hsuan Lin, Mary Lor, Catherine M. Abbott, David Harrich	2019	11
8	The protein arginine methyltransferase PRMT6 inhibits HIV-1 Tat nucleolar retention Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Alex J. Fulcher, Haran Sivakumaran, 煕史原田, Daniel J. Rawle, David Harrich, David A. Jans	2015	16
9	Specific Interaction between eEF1A and HIV RT Is Critical for HIV-1 Reverse Transcription and a Potential Anti-HIV Target PLoS Pathogens ·Dongsheng Li, Ting Wei, Daniel J. Rawle, Юсупова Яна Владимировна, Rui Wang, Dinesh C. Soares, 煕史原田, Haran Sivakumaran, Min‐Hsuan Lin, Kirsten Spann, Catherine M. Abbott, David Harrich	2015	15
10	A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4 ⁺ T Cells Human Gene Therapy ·Ann Apolloni, Min‐Hsuan Lin, Haran Sivakumaran, Dongsheng Li, Michael H. Kershaw, David Harrich	2013	18
11	Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6 Virology Journal ·Haran Sivakumaran, Min‐Hsuan Lin, Ann Apolloni, O Xu, 煕史原田, Dongsheng Li, Ting Wei, David Harrich	2013	11
12	Potent Inhibition of HIV-1 Replication by a Tat Mutant PLoS ONE ·Luke W. Meredith, Haran Sivakumaran, Lee Major, Andreas Suhrbier, David Harrich	2009	51
13	Isolated HIV-1 core is active for reverse transcription SHILAP Revista de lepidopterología ·David Warrilow, Deborah Stenzel, David Harrich	2007	28
14	HIV-1 Replication from After Cell Entry to the Nuclear Periphery Current HIV Research ·David Warrilow, David Harrich	2007	23
15	HIV Type 1 Inhibition by Protein Kinase C Modulatory Compounds AIDS Research and Human Retroviruses ·David Warrilow, Joy Gardner, Grant A. Darnell, Andreas Suhrbier, David Harrich	2006	52
16	Protein methylation is required to maintain optimal HIV-1 infectivity Retrovirology ·Siobhan Drummond Michele Cano, Raquel González Armas, Tracey Bodetti, Ann Apolloni, David Warrilow, Sabine C. Piller, David Harrich	2006	30
17	Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif Molecular and Cellular Biology ·Grant A. Darnell, Toni Antalis, Ricky W. Johnstone, Brett W. Stringer, Steven M. Ogbourne, David Harrich, Andreas Suhrbier	2003	63
18	The first strand transfer reaction of HIV-1 reverse transcription is more efficient in infected cells than in cell-free natural endogenous reverse transcription reactions Journal of Clinical Virology ·C. William Hooker, David Harrich	2003	16
19	Human Immunodeficiency Virus Type 1 Reverse Transcription Is Stimulated by Tat from Other Lentiviruses Virology ·C. William Hooker, Julie C. Scott, Ann Apolloni, SHEREE A. KRIGSMAN, David Harrich	2002	9
20	Tat is required for efficient HIV-1 reverse transcription The EMBO Journal ·David Harrich	1997	130

About David Harrich

David Harrich is a scholar working on Virology, Infectious Diseases, Immunology, Molecular Biology and Genetics, having authored 87 papers that have together received 4.5k indexed citations. Recurring topics across this work include HIV Research and Treatment (58 papers), HIV/AIDS drug development and treatment (31 papers), Virus-based gene therapy research (11 papers), RNA Research and Splicing (11 papers), RNA Interference and Gene Delivery (9 papers), Immune Cell Function and Interaction (9 papers), RNA and protein synthesis mechanisms (7 papers) and Viral Infections and Vectors (6 papers). The work is most often cited by research in Virology (1.9k citations), Infectious Diseases (1.4k citations), Immunology (868 citations), Neurology (528 citations) and Molecular Biology (2.0k citations). David Harrich has collaborated with scholars based in Australia, United States and China. Frequent co-authors include Richard B. Gaynor, F Wu, Haran Sivakumaran, Ronald T. Mitsuyasu, Joseph A. Garcia, León F. Garcı́a-Martı́nez, S.-H.I. Ou, David A. Jans, Kylie M. Wagstaff and Steven M. Heaton. Their work appears in journals such as Journal of Virology, The EMBO Journal, Virology Journal, PLoS ONE and Retrovirology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact